Frazier Life Sciences Management L.P. Buys Shares of 2,543,939 Vor Biopharma Inc. $VOR

Frazier Life Sciences Management L.P. bought a new stake in Vor Biopharma Inc. (NASDAQ:VOR) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 2,543,939 shares of the company’s stock, valued at approximately $33,275,000. Vor Biopharma makes up 0.9% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 26th biggest holding. Frazier Life Sciences Management L.P. owned 24.44% of Vor Biopharma as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of VOR. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at $36,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the 2nd quarter valued at $66,000. Chung Wu Investment Group LLC acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at $109,000. Finally, Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at $140,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on VOR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Monday, June 1st. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush increased their price target on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Trading Up 1.9%

Shares of VOR opened at $14.36 on Friday. Vor Biopharma Inc. has a 52 week low of $3.63 and a 52 week high of $65.80. The stock has a fifty day moving average of $15.09 and a 200-day moving average of $13.90.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. Sell-side analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Activity at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the completion of the transaction, the director directly owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. This trade represents a 11.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 3,002,903 shares of company stock valued at $49,412,176. 0.27% of the stock is currently owned by corporate insiders.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).